AI filing briefs · archive

8-K filings in September 2026, explained

1,853 material Form 8-K filings that 1,500 companies we cover made with the SEC in September 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).

Clear

5 of 1,853 briefs match

newest first · times in ET
BRTBRT Apartments Corp. Sep 17, 5:17 PM ET

BRT Apartments amends VNB New York loan, cutting interest rate to SOFR plus 210 bps

Positive financing Written later 1.018.01

BRT Apartments Corp. amended its loan agreement with VNB New York, LLC, lowering the facility's interest rate and minimum rate and the cap rate used to value secured assets. The company also said its board replenished its stock repurchase program to $10 million, and as of September 17, 2026, it can borrow $40 million under the facility.

  • Interest rate cut to three-month term SOFR plus 210 basis points, from plus 250 basis points
  • Minimum interest rate reduced to 5%, from 6%; asset valuation cap rate reduced to 6.25%, from 6.5%
  • Board increased stock repurchase program value to $10 million on September 17, 2026
  • Borrowing availability under the facility is $40 million as of September 17, 2026
Read the filing on SEC.gov ↗
GMRSGMR Solutions Inc. Sep 17, 4:54 PM ET

GMR Solutions refinances term loan, cuts margin 50 basis points, repays $200 million

Positive financing Written later 1.012.038.01

GMR Solutions' subsidiary GMR, Inc. amended its first lien term loan on September 17, 2026, lowering the interest margin from SOFR +3.25% to SOFR +2.75% and prepaying about $200 million with cash on hand. The company estimates the change will save about $28 million a year in cash interest expense, and the filing says pro forma cash would have been about $188 million, with total debt of about $4.27 billion, based on its June 30, 2026 balance sheet.

  • Voluntary prepayment of about $200 million of first lien term loans, using cash on hand, cutting principal to about $2.7 billion
  • Interest margin over SOFR reduced from +3.25% to +2.75%, a cut of about 50 basis points
  • Company estimates about $28 million of annual cash interest expense savings
  • About $32 million of cash paid on September 14, 2026 for payroll taxes on settled equity awards
Read the filing on SEC.gov ↗
TXNTEXAS INSTRUMENTS INC Sep 17, 4:11 PM ET

Texas Instruments raises quarterly dividend 7% to $1.52 per share, 23rd straight annual increase

Positive shareholder Written later 7.01

Texas Instruments said it will raise its quarterly cash dividend 7%, from $1.42 to $1.52 per share, or $6.08 annualized. The higher dividend is payable November 10, 2026, to holders of record on October 30, 2026, and is contingent on board declaration at its October regular meeting. The filing says the increase marks 23 consecutive years of dividend increases and reflects the company's commitment to return all free cash flow to owners over time.

  • Quarterly dividend rises 7%, from $1.42 to $1.52 per share
  • Annualized dividend is $6.08 per share
  • Payable November 10, 2026, to stockholders of record on October 30, 2026
  • Requires formal declaration by the board at its regular October meeting
Read the filing on SEC.gov ↗
FENCFENNEC PHARMACEUTICALS INC. Sep 17, 4:03 PM ET

Fennec Pharmaceuticals reports Phase 2 PEDMARK hearing-protection results in Japan

Positive other Written later 8.01

Fennec Pharmaceuticals said detailed results from the investigator-initiated Phase 2 STS-J01 study of PEDMARK in Japan met the primary endpoint, with hearing loss in 24.0% of patients versus a prespecified historical benchmark of 56.4%. The data were presented orally on September 17, 2026, at the 58th SIOP Annual Meeting, and the company said it is pursuing registration in Japan and exploring partnering or licensing options.

  • Primary endpoint met: ASHA-defined hearing loss in 24.0% (6 of 25) versus a prespecified historical benchmark of 56.4% (P=0.001)
  • 84.0% of patients had Grade 0 hearing loss by Brock criteria; no Grade 3 or Grade 4 hearing loss was observed
  • Objective tumor responses in 23 of 24 evaluable patients (95.8%)
  • Results presented at the 58th SIOP Annual Meeting in San Antonio, TX; Fennec is pursuing registration in Japan and exploring partnering or licensing for PEDMARK
Read the filing on SEC.gov ↗
CBANCOLONY BANKCORP INC Sep 17, 8:30 AM ET

Colony Bankcorp gets all regulatory approvals for First Reliance merger

Positive m&a Written later 5.028.01

Colony Bankcorp said on September 17, 2026 that it has received all required regulatory approvals for its merger with First Reliance Bancshares. The deal still needs shareholder approvals from both companies, with special meetings set for October 14, 2026, and the 8-K gives an expected closing date of November 1, 2026.

  • All required regulatory approvals received, announced September 17, 2026
  • Shareholder special meetings for both companies scheduled for October 14, 2026
  • Expected closing date of November 1, 2026, pending shareholder approvals and other customary conditions
  • Deal valued at approximately $163 million; combined company to have about $5 billion in total assets
Read the filing on SEC.gov ↗

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.

Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.